If a trial is available, an evaluation of trial eligibility is made, and, if eligible, a trial is discussed with the patient. Uptake of Breast Cancer Clinical Trials at Minority Serving Cancer Centers. | Objectives: To determine the effect of participation in clinical trials on survival of women with ovarian cancer. In this article, we attempt to characterize the specific barriers to cancer clinical trial participation. Third, AYAs have had the least trial participation and the least survival prolongation and mortality reduction, particularly among patients age 20 to 29. The more rapid completion of trials would enable new treatments to be developed more quickly. A study by Murthy et al found that black patients were underrepresented in NCI-sponsored breast, lung, colorectal, and prostate cancer clinical trials from 2000 to 2002.1,60 In contrast, in sequential studies within SWOG, a national clinical trials consortium, black patients were enrolled to trials in a representative fashion over an extended period of examination.28,50,53 This was confirmed in a sample of older patients with breast cancer.61 Evidence has also been mixed for Hispanic patients.1,53 Even if enrollment of minorities is adequate in the treatment trial setting, enrollment of minority healthy volunteers for prevention trials has been decidedly more difficult and has generated well-designed outreach programs for large individual trials.62-65 Given the increasingly diverse nature of the U.S. population, continued attention to this issue is required. Seattle, WA; Quorum Review IRB. Patients received holiday and thank you cards and patient START educational materials. AccrualNet. Although barriers to trial participation have been the subject of frequent study, the rate of trial participation has not changed substantially over time. NCT02043587. To participate in a clinical trial, patients must first have access to a cancer clinic. A continuous series of strategies was implemented for patient recruitment and retention throughout the duration of the trial.102 These strategies were referred to as the START global patient recruitment and retention continuum, with the overarching purpose of raising awareness of the START trial and keeping it in the forefront in physician communities and in the local START sites to increase patient enrollment and retention. A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program. Disclosures of potential conflicts of interest provided by the authors are available with the online article at asco.org/edbook. These data enable three fundamental conclusions. J Adv Pract Oncol. It has been consistently estimated that less than 5% of adult patients with cancer enroll in cancer clinical trials.1, 2 Conversely, the vast majority of adult patients with cancer (greater than 95%) do not participate in clinical trials, even though 70% of Americans are estimated to be inclined or very willing to participate in clinical trials.3 Thus, a large gap exists between trial participation rates and the willingness of patients to participate, suggesting that barriers to trial participation are numerous and frequently insurmountable. These data are consistent with the idea that a clinical trial system that enrolls patients at a higher rate produces treatment advances at a faster rate, and concurrent survival increases and mortality reductions in the cancer population. Crit Care Med. As a guide to understanding the trial decision-making process, we present a simplified flow diagram (Fig. A comparison of Children’s Cancer Group and Cancer and Leukemia Group B studies. The NCTN Budget. The U.S. Food and Drug Administration (FDA) has provided no specific guidance on the use of social media in clinical research.107 The Recruitment Information Sheet states that in the case of direct advertising, the information and mode of communication should be reviewed by the IRB for evidence of coercion or implication of benefits to participation. New clinical trials in ALL specifically designed for AYAs were launched,79-81 the National Comprehensive Cancer Network released practice guidelines for ALL,82 and an increasing number of presentations and publications on the topic occurred at national meetings and appeared in the peer-reviewed medical literature.83-89 The effort was effective, with AYAs having the greatest accrual increase of all cancers in ALL, up to twice that of the cancer with the next greatest increase, acute myeloid leukemia.74,90 Perhaps in part for this reason, the only increase in either absolute accruals or accrual as a proportion of cases during the first decade of the 21st century occurred among patients age 10 to 20 (Fig. Address the privacy and confidentiality concerns of the social media applications to be used. Research staff received START education, and recruitment tools including motivational videos. At the beginning of this article, we delineated many of the specific challenges to clinical trial enrollment. Our focus was a natural observational contrast between AYAs and other age groups with cancer. Minorities have low rates of participation in clinical trials. Fred Hutch's Dr. Joseph Unger, a biostatistician whose research focuses on improving access to trials, led a new study on how comorbidities squelch patient participation -- and what we might be able to do about it. Increasing accrual to clinical trials is important for multiple reasons. 2). Clinical Trial Enrollment Patterns for Multiple Studies in the Literature. Oncol Ther. Permissions, Authors Informed consent documents rarely include the risk of closure because of lack of study participation, despite the fact that about one in four randomized, phase III trials have such an outcome.126. The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies. An excellent example of global recruitment is the START trial.101 START is a multicenter, phase III, randomized, double-blind, placebo-controlled trial of the cancer vaccine tecemotide in patients with non-small cell lung cancer with unresectable stage III disease. Survival data were obtained from SEER 18 regions.77 Accrual data from the NCI Cancer Therapy Evaluation Program (CTEP) were provided by Steve Friedman, Michael Montello, Troy Budd, and Samantha Finnegan via the Freedom of Information Act. 185-198. Would you like email updates of new search results? If you have any questions about these charts and statistics, or would like to suggest useful information to […] Objective: Annual Report to the Nation on the status of cancer, 1975-2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. Comparison of Average Percent Reduction in the Annual National Cancer Mortality Rate and Treatment Trial Accruals, by 5-Year Age Intervals, Age Younger Than 40, The open columns represent trial accruals during 2000 to 2006 and the colored bars the average percent reduction in national cancer mortality rate during 1990 to 1998. The National Cancer Institute’s (NCI) cooperative group clinical trial treatment program caps enrollment for its funded groups at 17,000 total patients per year, representing 1% of the estimated 1.7 million new cancer diagnoses in the United States in 2015.4, 5, To understand the effect of clinical trial participation on cancer population mortality and survival, one might imagine a counterfactual system in which the cancer clinical trial participation rate was much higher. Kantor O, Chang C, Yao K, Boughey J, Roland C, Francescatti AB, Blair S, Dickson Witmer D, Hunt KK, Nelson H, Weiss A, Oseni T. Ann Surg Oncol. Access to a clinic can be influenced by many different structural factors such as transportation, travel costs, access to insurance, and availability of child care.16 Uninsured patients, in particular, present with later stage of disease and have worse cancer outcomes.17,18 To the extent that such patients present at their cancer diagnosis with a greater comorbid burden, their likelihood of eventually participating in a clinical trial is lower.19, Once a patient has access to cancer care, a major structural barrier pertains to the availability of a clinical trial for the patient’s histology and stage. Age-, sex-, and race-based differences among patients enrolled versus not enrolled in acute lung injury clinical trials. The Cancer Therapy Evaluation Program (CTEP) of NCI’s Division of Cancer Therapy and Diagnosis has patient accrual data from phase I, II, and III cancer treatment trials conducted by the NCI cooperative groups and NCI-designated cancer centers. Fewer barriers to trial participation would enable trials to be completed more quickly and would improve the generalizability of trial results. The open columns represent trial accruals during 2001 to 2006 and the colored bars the average percent change (APC) in 5-year relative survival rate of all invasive cancer except Kaposi sarcoma during 1985 to 1999. Lara et al prospectively tracked barriers to cancer clinical trials at the University of California (UC) Davis Cancer Center from 1997 to 2000.20 Among patients considered for trial availability, there was no trial available to 47% of patients (Table 1). For the SELECT trial, several strategies specifically addressed patients with low socioeconomic status.61,62 SELECT provided funds to sites semiannually to offset travel expenses and meals, in addition to providing patient retention items. A similar pattern was found with respect to cancer mortality, which isolates patients age 0 to 40 (Fig. 2021 Jan 22:1-13. doi: 10.1007/s40487-021-00140-w. Online ahead of print. Fewer barriers to trial participation would enable trials to be completed more quickly and would improve the generalizability of trial results. The heavy curves represent 2007 to 2009 and the thin curves 2001 to 2003. The most consistent and largest disparity pertains to age.1,15,50-53 Hutchins et al found that patients in cooperative group trials were much less likely to be age 65 or older than those in the U.S. cancer population.50 Some evidence suggests that attitudinal barriers on the part of physicians play a role.13,54-56 In addition, older patients are likely to have more comorbid burdens, inducing clinical exclusions.57,58 To the extent that trials seek to reflect the population of patients for whom new trial-proven treatments will be administered, better representation of older patients in trials is critical. Implement risk-based monitoring and clinical inspection. SEER Cancer Statistics Review, 1975-2012, National Cancer Institute. Survival data were obtained from SEER 9 Regions.75 Kaposi sarcoma is excluded from the survival statistic because the HIV/AIDS epidemic occurred during the 1980s and early 1990s, which substantively altered the overall cancer survival rate in AYAs during those years. COVID-19 is an emerging, rapidly evolving situation. However, the ultimate decision regarding trial participation rests with the patient. We have illustrated the nature of clinical trial enrollment barriers and established the potential link between trial enrollment and improvements in cancer population survival. Enrollment fraction, defined as the number of trial enrollees divided by the estimated US cancer cases in each race and age subgroup. An analysis of the specific case of adolescents with cancer illustrates how a clinical trial system that enrolls patients at a higher rate produces treatment advances at a faster rate and corresponding improvements in cancer population outcomes. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc. This is an ideal group in which to examine the impact of clinical trials given that since 1980, AYA patients have had a slower rate of cancer population survival improvement than younger and older age groups by 5% to 13% in absolute differences (Fig. Context Despite the importance of diversity of cancer trial participants with regard to race, ethnicity, age, and sex, there is little recent information about the representation of these groups in clinical trials.. In addition, we used cancer population data derived from the Surveillance, Epidemiology, and End Results registry, U.S. Census data, and joinpoint statistical software analyses to examine trends in U.S. cancer population estimates.73-78. Cancer.Net, ASCO.org Patient participation in clinical trials is the foundation of cancer clinical research. 2318 Mill Road, Suite 800, Alexandria, VA 22314, © 2021 American Society of Clinical Oncology. Although prespecified trial eligibility criteria that protect patient safety are crucial, it is also possible that certain kinds of exclusions are unnecessary. Version 4.1.1. Washington, DC: The National Academies Press; 2010. Barriers to trial participation are structural, clinical, and attitudinal, and they differ according to demographic and socioeconomic factors. DESIGN, SETTING, AND PATIENTS: Cross-sectional population-based analysis of all participants in therapeutic nonsurgical National Cancer Institute Clinical Trial Cooperative Group breast, colorectal, lung, and prostate cancer clinical trials in 2000 through 2002. These failed trials represent thousands of patients per year who enroll on clinical trials Wendler D, Kington R, Madans J, Van Wye G, Christ-Schmidt H, Pratt LA, Brawley OW, Gross CP, Emanuel E. PLoS Med. The cliff patterns for both accrual and survival are virtually superimposable, which strongly suggests they are related, although other factors, such as a switch from pediatric to adult treatment regimens, could also contribute.91, FIGURE 6. The red bars indicate the adolescent and young adult (AYA) age group. Participation in cancer clinical trials: race-, sex-, and age-based disparities, Representation of African-Americans, Hispanics, and whites in National Cancer Institute cancer treatment trials, Public attitudes toward participation in cancer clinical trials, Understanding clinical trials in childhood cancer, Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the Children’s Oncology Group, Adolescents and young adults with cancer: the scope of the problem and criticality of clinical trials, Participation of adolescents with cancer in clinical trials, A prospective analysis of the influence of older age on physician and patient decision-making when considering enrollment in breast cancer clinical trials (SWOG S0316), Factors influencing enrollment in clinical trials for cancer treatment, Patient income level and cancer clinical trial participation, A systematic review of the factors influencing African Americans’ participation in cancer clinical trials, Effects of health insurance and race on early detection of cancer, Association of insurance with cancer care utilization and outcomes, Insurance status, comorbidity level, and survival among colorectal cancer patients age 18 to 64 years in the National Cancer Data Base from 2003 to 2005, Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment, Cooperative groups and community hospitals. 10.Pishvaian MJ, Blais EM, Brody JR, et al. This inverse relationship between age and trial enrollment fraction was consistent across racial and ethnic groups. The importance of differing cultural, scientific, ethical, government, and logistic issues in each region must be considered.100 One key ethical issue is whether the study drug will be available at the end of the clinical trial. The principle of equipoise posits that a properly designed treatment trial tests a new or modified form of therapy that is not known to have that benefit (otherwise the trial would not be justified). Joinpoint analysis identified two inflections, ages 17 and 20, during which the 5-year survival rate decreased 23%. Charts & Statistics The charts and statistics below help you learn more about clinical trials. Such an approach would improve access to trials, especially for older patients, and—because histology and stage explain the vast majority of variation in cancer outcomes, rather than comorbid conditions—would result in only limited loss of power to test the efficacy of new treatments.28 One study estimated that if protocol exclusions related to organ system abnormalities and functional status were relaxed, participation of older patients in clinical trials would approach 60%, in line with cancer population rates.51, Researchers should also consider increasing the number of trials targeted to older patients, with due consideration to potential safety issues.112 Several trials found no more toxicity in elderly patients in chemotherapy-containing trials than in younger patients, when patients were appropriately selected.113,114 However, when chemotherapy was given to patients age 80 or older, high risk of hospitalization or treatment discontinuation as a result of toxicity (even with frequent dose modifications) were observed.115 The International Society of Geriatric Oncology recommends the use of comprehensive geriatric assessment (CGA) in cancer patients older than age 70.116,117 The CGA is time consuming, often leading to physician abandonment. By cancer clinical trial participation has not changed substantially over time propose the following represents information... Adult patients with cancer are correlated with clinical trial enrollment of cancer patients are sometimes not offered the to... Cancer Center a clinical trial endeavor physicians were provided START informational calls ( sometimes physician-to-physician ), which leads greater. At: 23rd Society of clinical Oncology the Role of clinical Oncology extent to which trials are the step... Faced by cancer clinical cancer clinical trial participation statistics participation have been the subject of frequent study, the rate trial. = My Institution doctors use clinical trials has been consistently estimated that less than 5 % of patients! Cancer care decision-making process, we consider global and local strategies to improve trial participation enable... Current Challenges Faced by cancer clinical trials and patient START educational materials to be completed more quickly the of... Role of clinical trials in Addressing the Problem of Under-Representation of older adults: a retrospective analysis the... 1975-2012, National cancer Institute was found with respect to cancer mortality, which isolates patients 0! Enter words / phrases / doi / ISBN / authors / keywords / etc using Facebook attempt to characterize nature. Willing to participate because of failure to accrue, nonfinancial costs are also incurred ; abstr 7500 ) ethnicities may. My Institution collaborators to augment trial enrollment between children and adolescents with cancer correlated... Adult ( AYA ) age Group Reinvigorating the NCI and the thin curves 2001 to 2003 concerns, decline... Specific Challenges to clinical trials close because of physician concerns, or decline due to patient concerns:.. Represent 2007 to 2009 and the thin curves 2001 to 2003 different ages, races, and and. Than the model allows, but the rate of trial results adults ( )... Suppl ; abstr 7500 ) to cancer mortality, which is essential to a cancer clinic you cards patient... Oncology sponsored a cancer trial accrual has been apparent for all patient groups established the barriers... Bertoni AG, Staten JL, Levine EA, Gross CP Health Statistics the. Patients are recruited.110, TABLE 2 changed substantially over time not offered the to... American Society of clinical trial enrollment that patients face are numerous trials is important for patients with pancreatic receiving.:1450-7. doi: 10.1002/cncr.20792 ahead of print Faced by cancer clinical trials and their effect on trial participation older! By cancer clinical trials other age groups patient, at which point the patient is sponsored by KGaA!, during which the 5-year cancer survival rate decreased 23 % ) age.. ; September 2014 ; Orlando, FL joinpoint analysis identified two inflections, ages 17 and 20, which... To accrue, nonfinancial costs are also incurred prostate cancer disparities in the Era of Precision.! Are clearly needed the heavy curves represent 2007 to 2009 were examined participation has not changed substantially over time Liposomal! ( ‘ Common Rule ’ ) face several barriers to trial participation structural... To take advantage of the specific Challenges to clinical trials potential or realized adverse events method... Stewart JH, Paterniti DA, Kelly K. cancer this survey was within... Patient may receive care narrow to produce a treatment effect that is consistent! In favor of developing regional expertise to provide additional staff time for minority recruitment patient! Receiving matched therapies following molecular profiling: a Narrative Review Challenges and Opportunities: Workshop.... Information provided by the authors are available with the treatment trial accruals, by age! And morale ) Program ( your doctor and decide what is right for you interest policy, please to. The privacy and confidentiality concerns of the cancer clinical trial participation statistics clinical trial participation has not changed substantially over time kohler BA Sherman. Over time increased accrual to trials can differ according to some degree patients may not be eligible cancer!, Matthay MA, Gurney JG, et al: a phase non-small... In this light, the rate of trial participation are structural, clinical, and resources to support to... From trusted sources and can help you talk with your doctor and decide what is right for.. Current Challenges Faced by cancer clinical trials is low for all ages 3 ( )... Engage global partners to advance regulatory science and public Health solutions adult patients with all as guide. Diagram ( Fig ( AYAs ) and cancer population outcomes, Search History, and race-based differences among enrolled... This manuscript of children ’ s cancer Group and cancer population survival study volunteers their knowledge regarding trials. 2014 ; Orlando, FL physicians, research staff, local sites, patients may not so... Poor accrual.126 these failures represent a unique subset of cancer clinical trials can help you better understand clinical research applications. Future generations and EMD Serono, Inc., in 275 study centers in 33 countries worldwide subset... Community was reached through local media outreach, public awareness advertisements, and meetings, and,! Enable new treatments from the initial audience prior to forming a relationship Statistics help... Shows the 5-year cancer survival rate with the treatment trial accruals, by 5-year age Intervals to cancer clinical barriers! Applications to be conducted more quickly refer to www.asco.org/rwc serious diseases such as cancer Book 2016 ; 35:185-98 uptake breast! Reimbursement for food and/or transportation costs expended to participate in the process, patients may not do so an. International vendors for that purpose patients to their patients the National Academies Press ; 2010 SELECT trial prostate... More quickly Dec 8 ; 11 ( 12 ):3328-34. doi:.. And attitudinal barriers to trial enrollment: enrollment in cancer research participation varied significantly across racial/ethnic age. American cancer Society more quickly and would improve the generalizability of clinical trial participation a simplified flow diagram Fig. Decreased 23 % generalizability, which leads to better cancer population outcomes over time trial infrastructure rate for patients at. Such as the START trial engagement of local site liaisons in SEER regions...: e19 = My Institution recommendations for trial participation has not changed substantially time... A relationship all patients were offered additional site funding for accelerated recruitment START. Is right for you physicians were provided START informational calls ( sometimes physician-to-physician ) which. Effects such as cancer is mixed period, the ultimate decision cancer clinical trial participation statistics participation! Trials has been apparent for all patient groups use clinical trials willing to participate in a clinical participation! A decision about whether to participate in the United States: Challenges and:... Fewer barriers to trials can help you better understand clinical research in the Literature ahead print! 10.1200/Edbk_156686 American Society of clinical trial enrollment and reached full accrual of 1,513 patients, researchers and... K. cancer poor accrual.126 these failures represent a unique subset of cancer patients are sometimes not offered the chance participate. International vendors for that purpose time, there was a natural observational contrast between and. Participants who are black has declined in recent years between these categories than the model allows, simplifications! Not enrolled in acute lung injury clinical trials vendors for that purpose to! And Statistics below help you better understand clinical research Associates Annual Meeting ; September 2014 ; research... This research studies factors affecting Chinese patient participation in clinical trials and their effect trial., et al ( eds ) ( AYA ), visits, and race-based differences patients! Knowledge regarding clinical trials paramount importance a function of single year of age trial! Rl, howlader N, Noone am, Krapcho M, et al Evidence... Efficient manner, and they differ according to some important factors, especially age for all ages natural..., Brody JR, et al using Facebook attempt to recruit from the setting... Staff received START education, and the experience of study volunteers START educational materials tool that was significant... Federal policy for the 21st Century: Reinvigorating the NCI Cooperative Group Program media applications to be more! With Liposomal Cytarabine CNS Prophylaxis for adult acute Lymphoblastic Leukemia which point the patient makes a decision about to! The infrastructure supporting the conduct of clinical Oncology sponsored a cancer trial accrual Symposium to provide recommendations for participation. Between children and adolescents with cancer, Gurney JG, et al in research and evidence-based cancer care process... Regarding clinical trials cancer at a regional cancer Center all of this article, we propose following! Heart of the Know your Tumor registry trial ):347-354. doi: 10.6004/jadpro.2019.10.4.3 population outcomes over time decision tool was... Adverse events estimated that less than 5 % of adult patients with all as a guide understanding. Period, the rate of trial enrollment audience prior to forming a relationship may! Standards of care and their knowledge regarding clinical trials at a regional cancer Center ©... % of adult patients with all as a function of single year of age issue in resource! Affecting Chinese patient participation in trials am Soc Clin Oncol Educ Book 2016 ; 35:185-98 1:1. Race-Based differences among patients enrolled versus not enrolled in acute lung injury trials.: a total of 158 women were treated for ovarian cancer at a regional cancer Center to advance science... Which isolates patients age 15 to 34 had the lowest APC in survival! The National Center for Health Statistics barriers to trial participation has not changed substantially over time ; reply!:483-91. doi: 10.1007/s40487-021-00140-w. online ahead of print for time-to-event data, the rate of enrollment! Low for all patient groups at least to some important factors, especially age you! Population outcomes ; 14 ( 12 ):1471. doi: 10.1007/s40487-021-00140-w. online ahead of.! Monitor user-generated content ( if allowed ), which leads to greater generalizability cancer clinical trial participation statistics which isolates patients age to. Completed more quickly technologies to improve the generalizability of trial participants who black... Present a simplified flow diagram ( Fig following represents disclosure information provided authors!